These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 26728598)

  • 41. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
    Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
    Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
    Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
    Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
    Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SHP2 phosphatase as a novel therapeutic target for melanoma treatment.
    Zhang RY; Yu ZH; Zeng L; Zhang S; Bai Y; Miao J; Chen L; Xie J; Zhang ZY
    Oncotarget; 2016 Nov; 7(45):73817-73829. PubMed ID: 27650545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma.
    Mataki H; Seki N; Chiyomaru T; Enokida H; Goto Y; Kumamoto T; Machida K; Mizuno K; Nakagawa M; Inoue H
    Int J Oncol; 2015 Mar; 46(3):1039-50. PubMed ID: 25522678
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sprouty2-modulated Kras signaling rescues Shp2 deficiency during lens and lacrimal gland development.
    Pan Y; Carbe C; Powers A; Feng GS; Zhang X
    Development; 2010 Apr; 137(7):1085-93. PubMed ID: 20215346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth.
    Bertotti A; Comoglio PM; Trusolino L
    J Cell Biol; 2006 Dec; 175(6):993-1003. PubMed ID: 17158954
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma.
    Schneeberger VE; Ren Y; Luetteke N; Huang Q; Chen L; Lawrence HR; Lawrence NJ; Haura EB; Koomen JM; Coppola D; Wu J
    Oncotarget; 2015 Mar; 6(8):6191-202. PubMed ID: 25730908
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.
    Zhou X; Agazie YM
    J Biol Chem; 2009 May; 284(18):12226-34. PubMed ID: 19261604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment.
    Luo R; Fu W; Shao J; Ma L; Shuai S; Xu Y; Jiang Z; Ye Z; Zheng L; Zheng L; Yu J; Zhang Y; Yin L; Tu L; Lv X; Li J; Liang G; Chen L
    Eur J Med Chem; 2023 May; 253():115305. PubMed ID: 37023678
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer.
    Kaur S; Elkahloun AG; Singh SP; Chen QR; Meerzaman DM; Song T; Manu N; Wu W; Mannan P; Garfield SH; Roberts DD
    Oncotarget; 2016 Mar; 7(9):10133-52. PubMed ID: 26840086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.
    Porter AC; Vaillancourt RR
    Oncogene; 1998 Sep; 17(11 Reviews):1343-52. PubMed ID: 9779982
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmaceutical SH2 domain-containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
    Liu JJ; Xin B; Du L; Chen L; Long Y; Feng GS
    Hepatology; 2023 May; 77(5):1512-1526. PubMed ID: 35503714
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects.
    Lade DM; Nicoletti R; Mersch J; Agazie YM
    Eur J Med Chem; 2023 Feb; 247():115017. PubMed ID: 36584630
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3.
    Burks J; Agazie YM
    Oncogene; 2006 Nov; 25(54):7166-79. PubMed ID: 16767162
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs).
    Wu CJ; Chen Z; Ullrich A; Greene MI; O'Rourke DM
    Oncogene; 2000 Aug; 19(35):3999-4010. PubMed ID: 10962556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.